Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis

Journal of Psychopharmacology

Volumn 32, Issue 6, 2018, Pages 702-710

  Gassó, Patricia ^a,b   Mas, Sergi ^a,b,c   Bioque, Miquel ^c,d   Cabrera, Bibiana ^c,d   Lobo, Antonio ^c,e   González Pinto, Ana ^c,f   Díaz Caneja, Covadonga M ^c,g   Corripio, Iluminada ^c,h,i   Vieta, Eduard ^b,c,d   Castro Fornieles, Josefina ^a,b,c,d   Sarró, Salvador ^c,j   Mané, Anna ^c,k   Sanjuan, Julio ^c,l   Llerena, Adrián ^c,m   Lafuente, Amalia ^a,b,c   Saiz Ruiz, Jerónimo ^c,n   Bernardo, Miguel ^a,b,c,d   Rodriguez, Natalia ^a   Boloc, Daniel ^a   Pina Camacho, Laura ^c,g   Parellada, Mara ^c,g   Alonso Solís, Anna ^c,i,o   Rabella, Mireia ^c,i,o   López, Purificación ^c,f   Zorrilla, Iñaki ^c,f   Barcones, Fe ^p   Fayed, Nicolás ^q   Nacher, Juan ^c,l   Hernandez Viadel, Miguel ^c,r   Bergé, Daniel ^c,k   Bulbena, Antoni ^i,k   Solé, Eva ^b,c,d   Del Mar Bonnin, Caterina ^b,c,d   Baeza, Immaculada ^d   de la Serna, Elena ^c,d   Contreras, Fernando ^c,s   Albacete, Auria ^c,s   García Portilla, María Paz ^c,t   Bobes, Julio ^c,t   Gutiérrez, Miguel ^c,f,u   Zabala, Arantzazu ^c,f,v   Morales Muñoz, Isabel ^c,w   Rodriguez Jimenez, Roberto ^c,w   Butjosa, Anna ^c,x   Usall, Judith ^c,x   Pomarol Clotet, Edith ^c,j   Landín Romero, Ramón ^y   Ibáñez, Ángela ^c,n   Cuesta, Manuel J ^z   Balanzá Martínez, Vicent ^c,l   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY OF ZARAGOZA   (Spain)

^f UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^j FIDMAG GERMANES HOSPITALÀRIES RESEARCH FOUNDATION   (Spain)

^k HOSPITAL DEL MAR   (Spain)

^l UNIVERSITY OF VALENCIA   (Spain)

^m UNIVERSITY OF EXTREMADURA   (Spain)

ⁿ HOSPITAL RAMÓN Y CAJAL   (Spain)

^o BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^p HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^q INSTITUTO DE INVESTIGACIÓN SANITARIA ARAGÓN IIS ARAGÓN   (Spain)

^r HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^s HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^t UNIVERSITY OF OVIEDO   (Spain)

^u Pharmacy Service   (Spain)

^v BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^w Institut de Recerca Sant Joan de Déu ^*  (Spain)

^x PARC SANITARI SANT JOAN DE DÉU   (Spain)

^y UNIVERSITY OF NEW SOUTH WALES   (Australia)

^z Universidad Pública de Navarra   (Spain)

more..

Author keywords

Antipsychotic; first episode of psychosis; gene; polymorphism; prolactin; side effect

Indexed keywords

DOPAMINE; NEUROLEPTIC AGENT; PROLACTIN; SEROTONIN;

ACE GENE; ADULT; ARTICLE; COHORT ANALYSIS; DRD2 GENE; FEMALE; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HIGH RISK POPULATION; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NTRK2 GENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

EID: 85047440652     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881118773026     Document Type: Article

References (57)

1. Aklillu E, Kalow W, Endrenyi L. (2007) CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics 17: 989–993.
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press.
3. Arnold E, Thebault S, Baeza-Cruz G. (2014) The hormone prolactin is a novel, endogenous trophic factor able to regulate reactive glia and to limit retinal degeneration. J Neurosci 34: 1868–1878.
4. Balsa JA, Sánchez-Franco F, Pazos F. (1998) Direct action of serotonin on prolactin, growth hormone, corticotropin and luteinizing hormone release in cocultures of anterior and posterior pituitary lobes: Autocrine and/or paracrine action of vasoactive intestinal peptide. Neuroendocrinology 68: 326–333.
5. Bernardo M, Bioque M, Cabrera B. (2017) Modelling gene-environment interaction in first episodes of psychosis. Schizophr Res 189: 181–189.
6. Bernardo M, Bioque M, Parellada M. (2013) Assessing clinical and functional outcomes in a gene-environment interaction study in first episodes of psychosis (PEPs). Rev Psiquiatr Salud Ment 6: 4–16.
7. Cabaleiro T, López-Rodríguez R, Ochoa D. (2013) Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Hum Psychopharmacol 28: 205–214.
8. Cabaleiro T, López-Rodríguez R, Román M. (2015) Pharmacogenetics of quetiapine in healthy volunteers: Association with pharmacokinetics, pharmacodynamics, and adverse effects. Int Clin Psychopharmacol 30: 82–88.
9. Calarge CA, Ellingrod VL, Acion L. (2009) Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics 19: 373–382.
10. Chen CY, Yeh YW, Kuo SC. (2016) Catechol-O-methyltransferase gene variants may associate with negative symptom response and plasma concentrations of prolactin in schizophrenia after amisulpride treatment. Psychoneuroendocrinology 65: 67–75.
11. Chien YL, Hwu HG, Fann CS. (2013) DRD2 haplotype associated with negative symptoms and sustained attention deficits in Han Chinese with schizophrenia in Taiwan. J Hum Genet 58: 229–232.
12. Choong E, Polari A, Kamdem RH. (2013) Pharmacogenetic study on risperidone long-acting injection: Influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects. J Clin Psychopharmacol 33: 289–298.
13. Chung CM, Wang RY, Chen JW. (2010) A genome-wide association study identifies new loci for ACE activity: Potential implications for response to ACE inhibitor. Pharmacogenomics J 10: 537–544.
14. Correia CT, Almeida JP, Santos PE. (2010) Pharmacogenetics of risperidone therapy in autism: Association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J 10: 418–430.
15. dos Santos Júnior A, Henriques TB, de Mello MP. (2015) Hyperprolactinemia in children and adolescents with use of risperidone: Clinical and molecular genetics aspects. J Child Adolesc Psychopharmacol 25: 738–748.
16. Duan J, Wainwright MS, Comeron JM. (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12: 205–216.
17. Emiliano AB, Fudge JL, (2004) From galactorrhea to osteopenia: Rethinking serotonin-prolactin interactions. Neuropsychopharmacology 29: 833–846.
18. Fitzgerald P, Dinan TG, (2008) Prolactin and dopamine: What is the connection? A review article. J Psychopharmacol 22: 12–19.
19. Freeman ME, Kanyicska B, Lerant A. (2000) Prolactin: Structure, function, and regulation of secretion. Physiol Rev 80: 1523–1631.
20. Gao S, Hu Z, Cheng J. (2012) Impact of catechol-o-methyltransferase polymorphisms on risperidone treatment for schizophrenia and its potential clinical significance. Clin Biochem 45: 787–792.
21. Gardner DM, Murphy AL, O’Donnell H. (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167: 686–693.
22. Glatt SJ, Faraone SV, Lasky-Su JA. (2009) Family-based association testing strongly implicates DRD2 as a risk gene for schizophrenia in Han Chinese from Taiwan Mol Psychiatry 14: 885–893.
23. González-Blanco L, Greenhalgh AM, Garcia-Rizo C. (2016) Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: A meta-analysis. Schizophr Res 174: 156–160.
24. Grupo de trabajo de la Guía de Práctica Clínica sobre la Esquizofrenia y el Trastorno Psicótico Incipiente. Fòrum de Salut Mental cPdCpeSNd (2009) Guía de Práctica Clínica sobre la Esquizofrenia y el Trastorno Psicótico Incipiente. Madrid, Spain.
25. Halbreich U, Kahn LS, (2003) Hyperprolactinemia and schizophrenia: Mechanisms and clinical aspects. J Psychiatr Pract 9: 344–353.
26. Houston J, Dharia S, Bishop JR. (2011) Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. Psychiatry Res 187: 74–79.
27. Houston JP, Fijal B, Heinloth AN. (2010) Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients. Psychiatry Res 175: 171–172.
28. Houston JP, Kohler J, Bishop JR. (2012) Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. J Clin Psychiatry 73: 1077–1086.
29. Ivanova SA, Osmanova DZ, Freidin MB. (2017) Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. World J Biol Psychiatry 18: 239–246.
30. Jenkins TA, (2008) Effect of angiotensin-related antihypertensives on brain neurotransmitter levels in rats. Neurosci Lett 444: 186–189.
31. Jenkins TA, Mendelsohn FA, Chai SY, (1997) Angiotensin-converting enzyme modulates dopamine turnover in the striatum. J Neurochem 68: 1304–1311.
32. Johnston CI, (1990) Biochemistry and pharmacology of the renin-angiotensin system. Drugs 39: 21–31.
33. Jönsson EG, Nöthen MM, Grünhage F. (1999) Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 4: 290–296.
34. Kapur S, Zipursky R, Jones C. (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157: 514–520.
35. Kuruvilla A, Peedicayil J, Srikrishna G. (1992) A study of serum prolactin levels in schizophrenia: Comparison of males and females. Clin Exp Pharmacol Physiol 19: 603–606.
36. Leucht S, Cipriani A, Spineli L. (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet 382: 951–962.
37. López-Rodríguez R, Román M, Novalbos J. (2011) DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. J Clin Psychopharmacol 31: 555–562.
38. Mas S, Gassó P, Lafuente A. (2016) Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: Role of dopamine, serotonin and glutamate candidate genes. Pharmacogenomics J 16: 439–445.
39. Mihara K, Kondo T, Suzuki A. (2000) Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene. Psychopharmacology 149: 246–250.
40. Mihara K, Suzuki A, Kondo T. (2001) Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am J Med Genet 105: 271–274.
41. Miura I, Zhang JP, Hagi K. (2016) Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis. Psychoneuroendocrinology 72: 1–10.
42. Montejo ÁL, Arango C, Bernardo M. (2016) Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. Rev Psiquiatr Salud Ment 9: 158–173.
43. Montgomery J, Winterbottom E, Jessani M. (2004) Prevalence of hyperprolactinemia in schizophrenia: Association with typical and atypical antipsychotic treatment. J Clin Psychiatry 65: 1491–1498.
44. Morales T, (2011) Recent findings on neuroprotection against excitotoxicity in the hippocampus of female rats. J Neuroendocrinol 23: 994–1001.
45. Noble EP, Blum K, Ritchie T. (1991) Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 48: 648–654.
46. Pacchiarotti I, Murru A, Kotzalidis GD. (2015) Hyperprolactinemia and medications for bipolar disorder: Systematic review of a neglected issue in clinical practice. Eur Neuropsychopharmacol 25: 1045–1059.
47. Peuskens J, Pani L, Detraux J. (2014) The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review. CNS Drugs 28: 421–453.
48. Rajkumar RP, (2014) Prolactin and psychopathology in schizophrenia: A literature review and reappraisal. Schizophr Res Treatment 2014: 175360.
49. Robinson D, Woerner MG, Alvir JM. (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56: 241–247.
50. Sakata K, Duke SM, (2014) Lack of BDNF expression through promoter IV disturbs expression of monoamine genes in the frontal cortex and hippocampus. Neuroscience 260: 265–275.
51. Sukasem C, Hongkaew Y, Ngamsamut N. (2016) Impact of pharmacogenetic markers of CYP2D6 and DRD2 on prolactin response in risperidone-treated Thai children and adolescents with autism spectrum disorders. J Clin Psychopharmacol 36: 141–146.
52. Thompson J, Thomas N, Singleton A. (1997) D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: Reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7: 479–484.
53. Yasui-Furukori N, Saito M, Nakagami T. (2010) Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 34: 537–540.
54. Young RM, Lawford BR, Barnes M. (2004) Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry 185: 147–151.
55. Zhang JP, Robinson DG, Gallego JA. (2015) Association of a schizophrenia risk variant at the DRD2 locus with antipsychotic treatment response in first-episode psychosis. Schizophr Bull 41: 1248–1255.
56. Zhang XR, Zhang ZJ, Zhu RX. (2011) Sexual dysfunction in male schizophrenia: Influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenomics 12: 1127–1136.
57. Zhu X, Bouzekri N, Southam L. (2001) Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure. Am J Hum Genet 68: 1139–1148.